Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the PD-1 Checkpoint Inhibitor, Cemiplimab, as Neoadjuvant Therapy in High Risk Localized, Locally Recurrent, and Regionally Advanced Cutaneous Squamous Cell Carcinoma: A Phase II Pilot Study

NCT04315701 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT04315701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04315701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the PD-1 Checkpoint Inhibitor, Cemiplimab, as Neoadjuvant Therapy in High Risk Localized, Locally Recurrent, and Regionally Advanced Cutaneous Squamous Cell Carcinoma: A Phase II Pilot Study
Lead sponsor
University of Southern California
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 17, 2020
Completion date
December 31, 2027
Enrollment
35 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent skin squamous cell carcinoma, resectable skin squamous cell carcinoma, stage i skin cancer, stage ii skin cancer, stage iii skin cancer